Orforglipron Drug Asset Due Diligence Report 2026

This Orforglipron Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Orforglipron can convert its Small molecule drug profile and GLP-1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Orforglipron (query alias: orforglipron)
Modality / target	Small molecule drug; GLP-1R; GLP-1R agonists
Highest global status	Approved
Originator	Chugai Pharmaceutical Co., Ltd.
Active developers	Eli Lilly & Co., Eli Lilly Canada, Inc., Chugai Pharmaceutical Co., Ltd.

The MCP disease footprint includes Obesity, Overweight, Diabetes Mellitus, Type 2. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-jRCT2031250526	Phase 3	募集中	7140	Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events Composite endpoint includes nonfatal myocardial infarction, nonfatal stroke, hospitalization or urgent visit due to heart failure, coronary revascularization, or all-cause death [Time Frame: Baseline up to end of study (about 5 years)]
ChiCTR2500113631	Phase 3	Pending	267	From baseline to Week 72:change in the WOMAC Pain subscale score
NCT07668336	Phase 3	Not yet recruiting	170	Change from Baseline in Hemoglobin A1c (HbA1c)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 3, Long-term Safety Study of LY3502970 in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone or in Combination With Oral Antihyperglycemic Medications (ACHIEVE-J)

Phase 3; n=401; evaluation: not stated. Reported fields: Number of Participants With Treatment Emergent Adverse Events (TEAEs) = 114 Participants ; Number of Participants With Treatment Emergent Adverse Events (TEAEs) = 107 Participants ; -

2624-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orforglipron: A Multiple Dose Titration Study in Chinese Participants with Obesity or Overweight with Weight-Related Comorbidities

Phase 1; n=24; evaluation: Positive. Reported fields: BMI = -3.48 kg/m^2

1254-OR: Orforglipron vs. Dapagliflozin in Type 2 Diabetes Inadequately Controlled with Metformin

Phase 3; n=962; evaluation: Positive. Reported fields: AE(leading to discontinuation) = Treatment discontinuations due to GI AE were 5.8-8.3% with OFG and 0.4% with DAPA. ; AE(leading to discontinuation) = Treatment discontinuations due to GI AE were 5.8-8.3% with OFG and 0.4% with DAPA. ; AE(leading to discontinuation) = Treatment discontinuations due to GI AE were 5.8-8.3% with OFG and 0.4% with DAPA.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Orforglipron addresses Obesity, Overweight, Diabetes Mellitus, Type 2. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2018-09-26	Eli Lilly to globally develop and commercialize Chugai's OWL-833 for the treatment of type 2 diabetes.	Preclinical	US$50.0M upfront; US$50.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Method for determining Orforglipron intermediate and enantiomer thereof by high performance liquid chromatography”. The milestone feed surfaced a patent-application signal described as “GLP-1r\GIPR\GCGR modulator in combination with THR-beta modulator for treatment of metabolic diseases”. The milestone feed surfaced a patent-application signal described as “Combination of a menin inhibitor with a pyrazolopiperidine GLP-1 receptor agonist for treating diabetes and obesity”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO